Tirzepatide (Mounjaro) Posted or Updated on 30 Jan 2025

Tirzepatide (Mounjaro) for weight loss is currently categorised as a grey drug on the Black Country Formulary (Positive NICE TA and /or awaiting local clarification on place in therapy) which will be reviewed as an output of the publication of TA1026.

It will remain this way while we work with system partners to develop models for our system, and whilst we await further direction from NHS England on their recommended models of care and any associated funding packages.

Unfortunately, this information does not align with the NICE TA release.

We kindly request that GPs do not prescribe Mounjaro for weight management until we have the pathways in place to enable patients to access the wrap around support required, which will increase their chances of making sustainable change, and the various checkpoints to ensure that patients remain on Mounjaro for an appropriate amount of time.